Blueprint Medicines Corporation logo
Blueprint Medicines Corporation BPMC

Quarterly report 2025-Q1
added 05-01-2025

report update icon

Blueprint Medicines Corporation Financial Statements 2011-2026 | BPMC

Annual Financial Statements Blueprint Medicines Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.96 B 5.31 B 2.66 B 6.27 B 6.12 B 3.07 B 3.11 B 3.06 B 913 M 287 M - - - -

Shares

62.9 M 60.6 M 59.6 M 58.5 M 54.5 M 47.8 M 43.9 M 37.8 M 27.5 M 18.2 M - - - -

Historical Prices

94.8 87.6 44.5 107 112 80.1 53.9 75.4 28.1 26.3 - - - -

Net Income

-67.1 M -507 M -558 M -644 M 314 M -348 M -237 M -148 M -72.5 M -52.8 M -40.3 M -20.9 M - -

Revenue

509 M 249 M 204 M 180 M 794 M 66.5 M 44.5 M 21.4 M 27.8 M 11.4 M - - - -

Cost of Revenue

20.2 M 8.54 M 17.8 M 17.9 M 425 K - - - - - - - - -

Interest Expense

656 K -946 K 2 M -1.49 M -366 K -100 K -180 K -76 K 551 K -429 K -98 K 226 K - -

EBITDA

16.3 M 11.7 M 11.7 M 6.48 M 6.56 M -356 M -243 M -150 M -71 M -50.7 M -39.2 M -20.3 M - -

Operating Expenses

- - - - - 428 M 292 M 173 M 100 M 63 M - - - -

General and Administrative Expenses

359 M 295 M 237 M 195 M 158 M 96.4 M 47.9 M 28 M 19.2 M 14.5 M 7.89 M 5.07 M - -

All numbers in USD currency

Quarterly Income Statement Blueprint Medicines Corporation

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

64.1 M 63.7 M 63.4 M 62.9 M 61.6 M 61.1 M 60.7 M 60.5 M 60.1 M 60 M 59.8 M 59.6 M 59.3 M 59.1 M 58.6 M 58.4 M 58 M 57.8 M 55.2 M 54.2 M 52.7 M 49.3 M 48.9 M 48.8 M 44.1 M 44 M 43.9 M 43.9 M 43.7 M 43.6 M 39.1 M 38.8 M 33.2 M 33.1 M 27.3 M 27.2 M 27.1 M 27.1 M 26.8 M 17.1 M 1.68 M 1.63 M 1.45 M 1.37 M 1.28 M - - - - - - - - - - - -

Net Income

496 K - -56.3 M -50 M 89.1 M - -134 M -133 M -130 M - -133 M -160 M -106 M - -117 M -108 M -99.7 M - 634 M -123 M -111 M -66.3 M -94.3 M -99.7 M -87.4 M -80.3 M -72.7 M -27 M -56.5 M -49 M -37.7 M -33.4 M -28 M -21.3 M -16.8 M -18.9 M -15.5 M -15.6 M -12.6 M -13 M -11.6 M -14.5 M -10.5 M -8.29 M -7.03 M - - - - - - - - - - - -

Revenue

149 M - 128 M 138 M 96.1 M - 56.6 M 57.6 M 63.3 M - 66 M 36.5 M 62.7 M - 24.2 M 27.3 M 21.6 M - 745 M 8.34 M 6.17 M 51.5 M 9.14 M 5.11 M 730 K 1.03 M 1.1 M 41.4 M 954 K 1.63 M 8.07 M 5.89 M 5.84 M 7.69 M 6.16 M 7.06 M 6.86 M 4.64 M 3.43 M 2.69 M 652 K - - - - - - - - - - - - - - - -

Cost of Revenue

2.8 M - 1.93 M 7.59 M 3.19 M - 2.78 M 2.32 M 3.18 M - 3 M 4.89 M 5.08 M - 3.79 M 6.49 M 102 K - 146 K 127 K 24 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

461 K - 587 K -1 K 376 K - -728 K -626 K 986 K - 396 K 632 K -453 K - -522 K -373 K -214 K - -192 K -23 K -201 K - -72 K -42 K -44 K - 2.8 M 2.44 M 2.39 M - 954 K 861 K 425 K - 158 K 131 K 61 K - 6 K -405 K -37 K - -94 K 1 K 18 K - - - - - - - - - - - -

EBITDA

4.46 M - - - 4.81 M - - - 3.68 M - 4.72 M - 1.63 M - 4.82 M 1.6 M 1.61 M - 4.89 M 3.24 M 1.57 M - 3.68 M 2.39 M 1.18 M - 3.08 M 1.91 M 780 K - 1.19 M 791 K 398 K - 1.19 M 782 K 386 K - 615 K 411 K 209 K - 416 K 273 K 134 K - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - 121 M 107 M 109 M 90.8 M 84.2 M 76.6 M 70.9 M 59.9 M 51.7 M 46.7 M 40.1 M 34.2 M 29.1 M 23 M 26 M 22.3 M 20.1 M 15.9 M 15.1 M 12 M 14.3 M 10.3 M 8.2 M 6.95 M - - - - - - - - - - - -

General and Administrative Expenses

95.8 M - 89.9 M 89.3 M 83.6 M - 70.7 M 71.9 M 71 M - 57.6 M 58.7 M 57.1 M - 49.8 M 49.3 M 42 M - 37.4 M 42.2 M 35.7 M - 25.6 M 21.9 M 16.6 M - 12 M 12.3 M 9.91 M - 7.38 M 6.83 M 5.68 M - 4.89 M 4.69 M 4.65 M - 4.22 M 3.84 M 2.77 M - 1.92 M 1.44 M 1.57 M - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Blueprint Medicines Corporation BPMC
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Blueprint Medicines Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Immatics N.V. Immatics N.V.
IMTX
$ 9.4 -1.16 % $ 591 M germanyGermany
Incyte Corporation Incyte Corporation
INCY
$ 90.47 0.02 % $ 17.7 B usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 215.49 -1.18 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.43 1.04 % $ 908 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.19 -5.95 % $ 578 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.72 18.96 % $ 8.25 M israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Exelixis Exelixis
EXEL
$ 41.39 -0.05 % $ 11.2 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.35 -3.57 % $ 344 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.59 -1.52 % $ 16.3 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.29 -3.05 % $ 822 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 69.54 -1.77 % $ 11.1 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 27.01 -2.14 % $ 1.55 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA